Results of the TRILOGY ACS Angiographic Cohort presented at TCT 2012

Study finds that prasugrel may reduce cardiovascular events among patients managed medically after an angiogram for acute coronary syndrome

2012-10-25

(Press-News.org) MIAMI, FL – OCTOBER 24, 2012 – A study has found that the anti-clotting medication prasugrel reduced cardiovascular events among patients who present with an acute coronary syndrome and are managed medically after an angiogram is performed to determine coronary anatomy. Results of the TRILOGY ACS trial, Angiographic Cohort were presented today at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.

Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 platelet inhibitor is beneficial in patients with unstable angina (UA) or non-ST segment elevation myocardial infarction (NSTEMI). Because a substantial fraction of these patients do not undergo revascularization after angiography, their optimal DAPT strategy is unknown.

The TRILOGY ACS trial compared prasugrel with aspirin versus clopidogrel with aspirin in the primary cohort of 7,243 UA/NSTEMI patients less than 75 years old who were medically managed without revascularization and had at least one high-risk criterion. The primary results of this study, presented at the European Society of Cardiology earlier this year, did not show any benefit for prasugrel with aspirin versus clopidogrel.

Patients were enrolled in 52 countries from June 2008 through September 2011 with median follow-up of 17 months. Those who weighed more than 60 kg were treated with a 10 mg maintenance dose of prasugrel versus 75 mg of clopidogrel; patients less than 60 kg received 5 mg of prasugrel.

Angiography was not required for enrollment, but if performed, evidence of coronary disease had to be demonstrated (at least one lesion > 30 percent stenosis or prior percutaneous coronary intervention/ coronary artery bypass graft surgery). Approximately 43% of the patients had angiography performed and coronary anatomy determined before being triaged to medical therapy. The results of this angiographic cohort were presented for the first time today at TCT.

Overall, in the TRILOGY ACS Trial, prasugrel did not reduce cardiovascular events among patients managed medically for ACS.

However, when treated with prasugrel compared to clopidogrel, patients who were triaged to medical therapy in the trial following angiography tended to have: Lower rates of the combined endpoint of cardiovascular disease/heart attack/stroke Lower rates of heart attack, stroke alone, and recurrent ischemic events Higher rates of bleeding "Though hypothesis-generating, these results are consistent with previous trials and suggest that when angiography is performed and coronary disease is confirmed, the benefits and risks of intensive antiplatelet therapy exist whether medical therapy or percutaneous coronary intervention is elected," said Stephen D. Wiviott, MD. Dr. Wiviott is a senior investigator with the TIMI Study Group, associate physician, Cardiovascular Division at Brigham and Women's Hospital, and associate professor of Medicine at Harvard Medical School.

The results of the TRILOGY ACS Angiographic Cohort trial will be presented on Wednesday October 24 at 12:32 PM EST in the Main Arena (Hall D) of the Miami Beach Convention Center.

### The trial was funded by Eli Lilly & Company and Daiichi Sankyo. Dr. Wiviott reported grant/research support from Eli Lilly & Company, AstraZeneca, Merck, and Eisai; and consulting fees/honoraria from Eli Lilly & Company, Daiichi Sankyo, AstraZeneca, BMS, Sanofi-Aventis, and Eisai.

About CRF The Cardiovascular Research Foundation (CRF) is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with cardiovascular disease through research and education. Since its inception in 1991, CRF has played a major role in realizing dramatic improvements in the lives of countless numbers of patients by establishing the safe use of new technologies and therapies in interventional cardiovascular medicine.

Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of the Cardiovascular Research Foundation. TCT gathers leading medical researchers and clinicians from around the world to present and discuss the latest developments in the field.

For more information, visit www.crf.org. END

ELSE PRESS RELEASES FROM THIS DATE:

Large-scale production of biofuels made from algae poses sustainability concerns

2012-10-25

WASHINGTON — Scaling up the production of biofuels made from algae to meet at least 5 percent -- approximately 39 billion liters -- of U.S. transportation fuel needs would place unsustainable demands on energy, water, and nutrients, says a new report from the National Research Council. However, these concerns are not a definitive barrier for future production, and innovations that would require research and development could help realize algal biofuels' full potential. Biofuels derived from algae and cyanobacteria are possible alternatives to petroleum-based fuels and ...

A sense of control, even if illusory, eliminates emotion-driven distortions of time

2012-10-25

CHAMPAIGN, Ill. — We humans have a fairly erratic sense of time. We tend to misjudge the duration of events, particularly when they are emotional in nature. Disturbingly negative experiences, for example, seem to last much longer than they actually do. And highly positive experiences seem to pass more quickly than negative ones. Researchers say they have found a way to lessen these emotion-driven time distortions. Having a sense of control over events reduces the influence of emotions on time perception, the researchers report. This is true even for highly reactive emotional ...

FFR-guided PCI shows cost-effectiveness when compared to medical therapy for stable CAD

2012-10-25

MIAMI, FL – OCTOBER 24, 2012 –A strategy of up-front percutaneous coronary intervention (PCI) for lesions confirmed to be obstructive by fractional flow reserve (FFR) was shown to be cost-effective in terms of quality-adjusted life years when compared to medical therapy alone. Results of the Cost-Effectiveness sub study of the FAME 2 trial were presented today at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional ...

Study confirms benefits of transcatheter aortic valve replacement over 3 years

2012-10-25

MIAMI, FL – OCTOBER 24, 2012 – A study found that transcatheter aortic valve replacement (TAVR) yielded lower mortality rates after three years compared with medical therapy in patients deemed to be ineligible for conventional aortic valve surgery. Results of the PARTNER Cohort B trial were presented today at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine. TAVR is the recommended ...

Results of the ISAR-LEFT MAIN 2 trial presented at TCT 2012

2012-10-25

MIAMI, FL – OCTOBER 24, 2012 – A study found that second-generation drug-eluting stents are safe and effective in the treatment of left main coronary artery lesions. Results of the ISAR-LEFT MAIN 2 trial were presented at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine. Patients undergoing invasive treatment of unprotected left main coronary artery (uLMCA) lesions are often ...

Scientists target bacterial transfer of resistance genes

2012-10-25

CHAMPAIGN, Ill. — The bacterium Streptococcus pneumoniae – which can cause pneumonia, meningitis, bacteremia and sepsis – likes to share its antibiotic-defeating weaponry with its neighbors. Individual cells can pass resistance genes to one another through a process called horizontal gene transfer, or by "transformation," the uptake of DNA from the environment. Now researchers report that they can interrupt the cascade of cellular events that allows S. pneumoniae to swap or suck up DNA. The new findings, reported in the journal PLoS ONE, advance the effort to develop ...

Research findings breathe new life into lung disease

2012-10-25

TORONTO, Oct. 24, 2012--It turns out the muscle cells on the outside of blood vessels have been wrongly accused for instigating lung disease. New research shows that while these muscle cells are responsible for constricting or dilating the blood vessels, they are not responsible for sensing the amount of oxygen that gets to the lungs. That message comes from the endothelial cells – special cells that line the blood vessels – along a "signalling pathway." When a person is low on oxygen, blood vessels throughout the body expand to improve the delivery of this vital molecule ...

Is obesity irreversible? Timing is key in weight loss, U-M research shows

2012-10-25

ANN ARBOR, Mich. — Joint research between the University of Michigan and the Argentina-based National Council of Science and Technology (CONICET) has shed light on one of the most frustrating mysteries of weight loss – why the weight inevitably comes back. A novel animal model showed that the longer mice remained overweight, the more "irreversible" obesity became, according to the new study that appeared online ahead of print Oct.24 in the Journal of Clinical Investigation. Over time, the static, obese state of the mice reset the "normal," body weight set point to ...

Mesh-covered stent helps restoration of blood flow in heart attack patients undergoing PCI

2012-10-25

MIAMI, FL – OCTOBER 24, 2012 – A clinical trial found that the use of a next generation, micronet, mesh-covered stent demonstrated improved restoration of blood flow to heart tissue, compared to the use of either bare-metal or drug-eluting stents in heart attack patients undergoing angioplasty. Results of the MASTER trial were presented today at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium and will appear in the November 6th issue of the Journal of the American College of Cardiology. Sponsored by the Cardiovascular Research Foundation, ...

Knee replacement not an 'easy solution' for obese patients

2012-10-25

ROSEMONT, IL–Obese patients have a greater risk of complications following total knee replacement surgery, including post-surgical infections, according to a new literature review recently published in the Journal of Bone and Joint Surgery (JBJS). Because of complications, obese patients are more likely to require follow-up surgery (revision). Obesity is reaching epidemic proportions, particularly in the United States, and is a well-documented risk factor for the development of osteoarthritis. Arthritis is initially treated nonsurgically, but total joint replacement often ...